SecBot SecBot
SECBOTREPLAY Home › Report › STOK

STOK · Stoke Therapeutics appointed Dr

Stoke Therapeutics, Inc. · 8-K filed Apr 7, 2026 at 16:05 ET

At the news

NEUTRALIMPACT 3/10

8-K filed Apr 7, 2026 at 16:05 ET

Stoke Therapeutics appointed Dr. Clare Kahn, a seasoned biotech executive with deep regulatory and drug development expertise, to its board of directors. The move strengthens governance ahead of key Phase 3 data readouts for its lead candidate, zorevunersen, in Dravet syndrome.

  • Dr. G. Clare Kahn, Ph.D., was appointed to Stoke's Board of Directors effective April 3, 2026.
  • Dr. Kahn brings over three decades of industry experience, including senior roles at Pfizer, GSK, and X-VAX Technology Inc., with expertise in rare disease drug development and regulatory strategy.
  • She was also appointed chairperson of the Research and Development Committee and to the Nominating and Corporate Governance Committee.
  • The board size was increased to ten directors to accommodate the appointment.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access